Subtopic Deep Dive
EGFR Tyrosine Kinase Inhibitors in Lung Cancer
Research Guide
What is EGFR Tyrosine Kinase Inhibitors in Lung Cancer?
EGFR Tyrosine Kinase Inhibitors (TKIs) are targeted therapies like gefitinib and osimertinib that inhibit EGFR mutations in non-small cell lung cancer (NSCLC), achieving 70-80% response rates in mutation-positive patients.
First-generation TKIs like gefitinib target EGFR exon 19 deletions and L858R mutations, while third-generation osimertinib overcomes T790M resistance. FLAURA trial by Soria et al. (2018, 4982 citations) established osimertinib as first-line standard with superior progression-free survival. Over 20,000 citations across key trials document sequencing and combination strategies.
Why It Matters
EGFR TKIs exemplify precision oncology, with osimertinib in FLAURA (Soria et al., 2018) extending median survival to 38.6 months versus 31.8 months for first-generation TKIs (Ramalingam et al., 2020). In Asian cohorts, PIONEER study (Shi et al., 2014) reported 51.4% EGFR mutation prevalence, guiding testing protocols. ADAURA trial (Wu et al., 2020) showed 80% reduction in recurrence risk post-resection, transforming adjuvant care and reducing healthcare costs by prioritizing mutation testing.
Key Research Challenges
T790M Acquired Resistance
Up to 60% of patients develop T790M mutation after first-generation TKI progression. Mok et al. (2016, 3213 citations) demonstrated osimertinib superiority over chemotherapy in T790M-positive cases. Liquid biopsy monitoring remains inconsistent for early detection.
C797S and Novel Mutations
Post-osimertinib resistance often involves C797S, limiting third-generation efficacy. No approved fourth-generation TKIs exist despite preclinical promise. Combination strategies like osimertinib-BETi need phase III validation.
Optimal Sequencing Strategies
Debate persists on first- versus third-generation TKI initiation and combo sequencing. Ramalingam et al. (2020) confirmed osimertinib OS benefit, but upfront use may accelerate non-T790M resistance. Biomarker-driven trials are underpowered.
Essential Papers
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al. · 2017 · New England Journal of Medicine · 5.0K citations
Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and lower rates of serious adv...
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis, Élisabeth Brambilla, Masayuki Noguchi et al. · 2011 · Journal of Thoracic Oncology · 4.8K citations
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine et al. · 2016 · The Lancet · 3.3K citations
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn et al. · 2016 · New England Journal of Medicine · 3.2K citations
Osimertinib had significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M-positive advanced non-small-cell lung cancer (including those with CNS metastases) in who...
Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC
Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard et al. · 2019 · New England Journal of Medicine · 2.6K citations
Among patients with previously untreated advanced NSCLC with an <i>EGFR</i> mutation, those who received osimertinib had longer overall survival than those who received a comparator EGFR-TKI. The s...
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Silvia Novello, Fabrice Barlési, Raffaele Califano et al. · 2016 · Annals of Oncology · 2.6K citations
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
Yi‐Long Wu, Masahiro Tsuboi, Jie He et al. · 2020 · New England Journal of Medicine · 1.6K citations
In patients with stage IB to IIIA <i>EGFR</i> mutation-positive NSCLC, disease-free survival was significantly longer among those who received osimertinib than among those who received placebo. (Fu...
Reading Guide
Foundational Papers
Start with Shi et al. (2014) PIONEER for 51.4% EGFR prevalence in Asians (1507 citations), then Travis et al. (2011) adenocarcinoma classification (4761 citations) for histological context.
Recent Advances
Prioritize Soria et al. (2018) FLAURA (4982 citations) for first-line osimertinib, Ramalingam et al. (2020) OS update (2641 citations), Wu et al. (2020) ADAURA adjuvant (1649 citations).
Core Methods
RCTs assess PFS/OS via RECIST (FLAURA/AURA3); ctDNA NGS for T790M (PIONEER); adjuvant DFS in resected EGFR+ (ADAURA). Python analyzable Kaplan-Meier curves in NEJM supplements.
How PapersFlow Helps You Research EGFR Tyrosine Kinase Inhibitors in Lung Cancer
Discover & Search
Research Agent uses searchPapers and exaSearch to retrieve FLAURA trial (Soria et al., 2018) plus 50+ related osimertinib studies; citationGraph reveals T790M progression from Mok et al. (2016) to Ramalingam et al. (2020); findSimilarPapers expands to ADAURA (Wu et al., 2020).
Analyze & Verify
Analysis Agent applies readPaperContent to extract HRs from Soria et al. (2018) FLAURA abstract; verifyResponse with CoVe cross-checks mutation rates against Shi et al. (2014) PIONEER; runPythonAnalysis computes pooled response rates from trial data via pandas, graded A by GRADE for level 1 evidence.
Synthesize & Write
Synthesis Agent detects gaps in fourth-generation TKI trials via contradiction flagging across Mok/Wu papers; Writing Agent uses latexEditText for trial comparison tables, latexSyncCitations for 20+ refs, latexCompile for publication-ready review; exportMermaid visualizes resistance pathway cascades.
Use Cases
"Extract survival data from FLAURA and AURA3 trials for meta-analysis"
Research Agent → searchPapers('FLAURA AURA3') → Analysis Agent → readPaperContent(Soria 2018, Mok 2016) → runPythonAnalysis(pandas meta-analysis of HRs/CIs) → CSV export of pooled OS/PFS estimates.
"Write LaTeX review section on osimertinib adjuvant benefits"
Synthesis Agent → gap detection(ADAURA Wu 2020) → Writing Agent → latexEditText('ADAURA DFS 89% reduction') → latexSyncCitations(20 EGFR papers) → latexCompile → PDF with resistance pathway Mermaid diagram.
"Find GitHub repos analyzing EGFR TKI resistance mechanisms"
Research Agent → paperExtractUrls(Mok 2016) → paperFindGithubRepo → githubRepoInspect(top mutation modeling code) → runPythonAnalysis(reproduce T790M binding affinities) → verified simulation outputs.
Automated Workflows
Deep Research workflow conducts systematic review of 100+ EGFR TKI trials (searchPapers → citationGraph → GRADE grading), producing structured report ranking osimertinib evidence. DeepScan's 7-step chain analyzes FLAURA/AURA3 progression data with CoVe verification and Python survival curves. Theorizer generates hypotheses for C797S combo therapies from resistance mutation patterns in Wu/Ramalingam papers.
Frequently Asked Questions
What defines EGFR TKIs in NSCLC?
EGFR TKIs selectively block mutant EGFR signaling in NSCLC; first-generation (gefitinib) for exon 19/L858R, third-generation (osimertinib) for T790M (Soria et al., 2018).
What are key methods for EGFR TKI evaluation?
Phase III RCTs like FLAURA (osimertinib vs gefitinib, PFS HR 0.46) and AURA3 (osimertinib vs chemo, ORR 71%) use RECIST criteria; liquid biopsy detects T790M ctDNA (Mok et al., 2016).
What are seminal papers?
Soria et al. (2018, 4982 citations) FLAURA established first-line osimertinib; Mok et al. (2016, 3213 citations) AURA3 for T790M; Wu et al. (2020) ADAURA for adjuvant use.
What open problems exist?
Fourth-generation TKIs for C797S resistance lack approval; optimal upfront osimertinib timing risks novel mutations; real-world ctDNA monitoring standardization needed beyond trials.
Research Lung Cancer Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching EGFR Tyrosine Kinase Inhibitors in Lung Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.